ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Berberine Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03029390
Recruitment Status : Active, not recruiting
First Posted : January 24, 2017
Last Update Posted : February 22, 2018
Sponsor:
Information provided by (Responsible Party):
Karina Griselda Pérez Rubio, University of Guadalajara

Brief Summary:

Pre diabetes (PD) is a term that refers to alterations in glucose homeostasis, including impaired fasting glucose (IFG), Imparied glucose tolerance (IGT) or both, involving a higher risk to develop type 2 diabetes mellitus (T2DM) in 10 years.

The efficacy of pharmacotherapy in the prevention of diabetes in adults with prediabetes has been demonstrated, the first line of pharmacology treatment is metformin, on the other hand, the traditional Chinese and Ayurverica medicine offer potential active substances for the treatment of hyperglucemia like berberine.

Berberine is an extract with hypoglycemic effects in animal models as well as in clinical trials in type 2 diabetes mellitus even compared to metformin, for this reason comparing it's activity against metformin in prediabetes would provide impact information on a new alternative treatment and compare with the standard pharmacological treatment.

The aim of the study evaluate the effect of administration of berberine versus metaformine on glycemic control, insulin secretion and insulin sensitivity in patients with pre diabetes.

The investigators hypothesis is that the administration of berberine versus metformin modifies glycemic control, insulin sensitivity and insulin secretion in patients with prediabetes.


Condition or disease Intervention/treatment Phase
Prediabetes Impaired Fasting Glucose Impaired Glucose Tolerance Dietary Supplement: Berberine Drug: Metformin Phase 4

Detailed Description:

A randomized, double-blind, placebo-controlled clinical trial in 28 patients with a diagnosis of prediabetes (IFG and IGT) in accordance with the American Diabetes Association with out treatment.

They will be assigned randomly two groups of 14 patients, one of the groups will receive 850 mg of metformin twice at day (before breakfast and before dinner) and one pill of placebo (before lunch) for 14 weeks. There will be a running period, starting with a dose of 500 mg the first week, the second week increasing to 1000 mg and from the third to the fourteenth week will be a dose of 1500 mg.

The other group will receive 500 mg of berberine three times at day (each one before the mealtime) for14 weeks. There will be a running period, starting with a dose of 850 mg the first week, the second week dose of 850 mg of metformin plus one placebo pill and from the third week to the fourteenth week will be a dose of 1700 mg ( two 850 mg metformin pills) plus one placebo pill.

They will be measured fasting blood glucose, postprandial glucose levels and glycosylated hemoglobin, and will be calculated Area Under Curve of glucose and insulin, total insulin secretion (Insolinogenic index), first-phase of insulin secretion (Strumvoll index) and insulin sensitivity (Matsuda index).

This protocol it's already approved by the local ethics committee and written informed consent it's going to be obtained from all volunteers.

Statistical analysis will be presented through measures of central tendency and dispersion, average and deviation standard for quantitative variables; frequencies and percentage for qualitative variable. Qualitative variables will be analyzed by X2, will be used for differences inter-group Mann-Whitney U Test and Wilcoxon Test for the within-groups differences. It will be considered statistical significance p≤0.05.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Administration of Berberine Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Patients With Prediabetes
Study Start Date : March 2016
Actual Primary Completion Date : February 2018
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy Prediabetes

Arm Intervention/treatment
Experimental: Berberine hydrochloride

Berberine capsules, 500 mg, three per day before each meal during 12 weeks.

The patients will have a forced titration period:

First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study, they will be receive three 500 mg capsules (before each meal)

Dietary Supplement: Berberine

Berberine capsules, 500 mg, three per day before each meal during 14 weeks.

The patients will have a running period during two weeks:

First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study (14 week), they will be receive three 500 mg

Other Name: Berberine hydrochloride

Experimental: Metformin

Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 12 weeks.

The patients will have a forced titration period:

First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).

From the third week until the end of the study, they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal).

Drug: Metformin

Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 14 weeks.

The patients will have a running period:

First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).

From the third week until the end of the study (14 week), they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal).





Primary Outcome Measures :
  1. Fasting glucose levels [ Time Frame: Baseline to week 14 ]
    The fasting glucose levels will be evaluated at baseline and week 14 with enzymatic/ colorimetric techniques and the entered values reflect the fasting glucose level at week 14

  2. postprandial glucose levels [ Time Frame: baseline to week 14 ]
    Postprandial glucose will be evaluated at baseline week 14 after a oral glucose tolerance test with enzymatic/ colorimetric techniques and the entered values reflect the insulin sensitivity at week 14

  3. Glycosylated hemoglobin [ Time Frame: baseline to week 14 ]
    Glycosylated hemoglobin will be evaluated at baseline and week 14 by Elisa and the entered values reflect the glycosylated hemoglobin at week 14

  4. Total insulin secretion [ Time Frame: baseline to week 14 ]
    Total insulin secretion will be calculated at baseline and week 14 with insulinogenic index and the entered values reflect the total insulin secretion at week 14

  5. First phase of insulin secretion [ Time Frame: baseline to week 14 ]
    The first phase of insulin secretion will be calculated at baseline and week 14 with Strumvoll index and the entered values reflect the first phase of insulin secretion at week 14

  6. Insulin sensitivity [ Time Frame: baseline to week 14 ]
    Insulin sensitivity will be calculated at baseline and week 14 with Matsuda index and the entered values reflect the insulin sensitivity at week 14


Secondary Outcome Measures :
  1. Body Weight [ Time Frame: Baseline to week 14 ]
    The body weight will be measured at baseline, week 3, week 6, week 10, and week 14 with a bioimpedance balance and the entered values reflect the body weight at week 14

  2. Body Mass Index [ Time Frame: Baseline to week 14 ]
    Body Mas Index will be calculated at baseline, week 3, week 6, week 10, and week 14 with the Quetelet index formula and the entered values reflect the body mass index at week 14

  3. Body fat percentage [ Time Frame: Baseline to week 14 ]
    Body fat percentage will be evaluated at baseline, week 3, week 6, week 10, and week 14 by Bioimpedance technique and the entered values reflect the body fat percentage at week 14

  4. Waist circumference [ Time Frame: Baseline to week 14 ]
    Waist circumference will be evaluated at baseline, week 3, week 6, week 10 and week 14 by World Health Organization technique and the entered values reflect the waist circumference mesure at week 14

  5. Blood pressure [ Time Frame: Baseline to week 14 ]
    Blood pressure will be measured at baseline,week 3, week 6, week 10 and week week 14 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 14

  6. Total cholesterol [ Time Frame: Baseline to week 14 ]
    Total cholesterol levels will be evaluated at baseline and week 14 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 14

  7. Triglycerides levels [ Time Frame: Baseline to week 14 ]
    Triglycerides levels will be evaluated at baseline and week 14 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 14

  8. High density lipoprotein (c-HDL) levels [ Time Frame: Baseline to week 14 ]
    c-HDL levels will be evaluated at baseline and week 14 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 14

  9. Low density lipoprotein (c-LDL) levels [ Time Frame: Baseline to week 14 ]
    c-LDL levels will be will be calculated at baseline and week 14 with Friedewald Formula and the entered values reflect the c-HDL level at week 14

  10. Alanine aminotransferase (ALT) levels [ Time Frame: Baseline to week 14 ]
    ALT levels will be evaluated at baseline and week 14 with enzymatic/colorimetric techniques

  11. Aspartate aminotransferase (AST) levels [ Time Frame: Baseline to week 14 ]
    AST levels will be evaluated at baseline and week 14 with enzymatic/colorimetric techniques

  12. Creatinine levels [ Time Frame: Baseline to week 14 ]
    Creatinine levels will be evaluated at baseline and week 14 with enzymatic/colorimetric techniques



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   31 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients both sexes
  • Age between 31 and 60 years
  • Diagnosis of prediabetes according 2 ADA criteria (fasting blood glucose levels between 100-125 mg/dl and postprandial blood glucose levels after an oral glucose tolerance test with 75 of oral glucose between 140-199 mg/dl)
  • Body Mass Index from 25 to 34.9kg/m2
  • Informed consent signed

Exclusion Criteria:

  • Women with confirmed or suspected pregnancy
  • Women under lactation and/or puerperium
  • Hypersensibility to ingredients of intervention
  • Physical impossibility for taking pills
  • Known uncontrolled renal, hepatic, heart or thyroid diseased
  • Diabetes diagnosis
  • Previous treatment for glucose
  • Body Mass Index ≥35 kg/m2
  • Glycosylated hemoglobin > 6.5%
  • Triglycerides ≥500 mg/dL
  • Total cholesterol ≥240 mg/dL
  • Low density lipoprotein (c-LDL) ≥190 mg/dL
  • Blood Pressure ≥140/90 mmHg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03029390


Locations
Mexico
Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara
Guadalajara, Jalisco, Mexico, 44340
Sponsors and Collaborators
University of Guadalajara
Investigators
Principal Investigator: KARINA GRISELDA PEREZ, PhD University of Guadalajara

Responsible Party: Karina Griselda Pérez Rubio, PhD, University of Guadalajara
ClinicalTrials.gov Identifier: NCT03029390     History of Changes
Other Study ID Numbers: BM-Prediabetes
First Posted: January 24, 2017    Key Record Dates
Last Update Posted: February 22, 2018
Last Verified: February 2018

Keywords provided by Karina Griselda Pérez Rubio, University of Guadalajara:
Prediabetes
hyperglycemia
Impaired Fasting Glucose
Metformin
Berberine
glucose intolerance

Additional relevant MeSH terms:
Insulin Resistance
Prediabetic State
Glucose Intolerance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Diabetes Mellitus
Endocrine System Diseases
Hyperglycemia
Insulin
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs